Business ❯ Pharmaceuticals ❯ Acquisitions

Mergers and Acquisitions

Novo Nordisk Pfizer Novartis Alkermes plc Novo Nordisk vs Pfizer

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

The cash-plus-CVR deal followed FTC concerns over Novo Nordisk’s bid, setting expectations for near-term dilution.

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion